Cargando…
Glycoconjugate vaccines: classic and novel approaches
Glycoconjugate vaccines, obtained by carbohydrates covalently bound to protein carriers, have contributed to fight diseases such as meningitidis, pneumonia and typhoid fever. Despite new technologies such as RNA and adenovirus based vaccine have now reached the market, these approaches are unable to...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8225458/ https://www.ncbi.nlm.nih.gov/pubmed/34169357 http://dx.doi.org/10.1007/s10719-021-09997-5 |
_version_ | 1783712095205851136 |
---|---|
author | Adamo, Roberto |
author_facet | Adamo, Roberto |
author_sort | Adamo, Roberto |
collection | PubMed |
description | Glycoconjugate vaccines, obtained by carbohydrates covalently bound to protein carriers, have contributed to fight diseases such as meningitidis, pneumonia and typhoid fever. Despite new technologies such as RNA and adenovirus based vaccine have now reached the market, these approaches are unable to target carbohydrates which are key virulence factors. This issue intends to provide an overview on relevant directions where the field is evolving and serve as starting point to increase interest in this exciting and fundamental part of vaccinology. |
format | Online Article Text |
id | pubmed-8225458 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Springer US |
record_format | MEDLINE/PubMed |
spelling | pubmed-82254582021-06-25 Glycoconjugate vaccines: classic and novel approaches Adamo, Roberto Glycoconj J Editorial Glycoconjugate vaccines, obtained by carbohydrates covalently bound to protein carriers, have contributed to fight diseases such as meningitidis, pneumonia and typhoid fever. Despite new technologies such as RNA and adenovirus based vaccine have now reached the market, these approaches are unable to target carbohydrates which are key virulence factors. This issue intends to provide an overview on relevant directions where the field is evolving and serve as starting point to increase interest in this exciting and fundamental part of vaccinology. Springer US 2021-06-25 2021 /pmc/articles/PMC8225458/ /pubmed/34169357 http://dx.doi.org/10.1007/s10719-021-09997-5 Text en © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2021 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
spellingShingle | Editorial Adamo, Roberto Glycoconjugate vaccines: classic and novel approaches |
title | Glycoconjugate vaccines: classic and novel approaches |
title_full | Glycoconjugate vaccines: classic and novel approaches |
title_fullStr | Glycoconjugate vaccines: classic and novel approaches |
title_full_unstemmed | Glycoconjugate vaccines: classic and novel approaches |
title_short | Glycoconjugate vaccines: classic and novel approaches |
title_sort | glycoconjugate vaccines: classic and novel approaches |
topic | Editorial |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8225458/ https://www.ncbi.nlm.nih.gov/pubmed/34169357 http://dx.doi.org/10.1007/s10719-021-09997-5 |
work_keys_str_mv | AT adamoroberto glycoconjugatevaccinesclassicandnovelapproaches |